Full-Time

Specialist IS Architect-Endpoint Management

Digital Workplace Experience

Posted on 7/27/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
IT & Security (2)
,
Required Skills
PowerShell
Bash
Agile
iOS/Swift
DevOps
Requirements
  • Doctorate degree / Master's degree / Bachelor's degree and 8 to 13 years in Information Systems experience
  • Degree in Computer Science, Information Systems, Engineering, or Life Sciences.
  • Skilled in designing solutions for Digital Workspace technologies, including mobility, virtualization, and end-user devices.
  • Experience creating strategic execution plans to address gaps between current and future business goals.
  • Expert in applying enterprise architecture frameworks to enhance reliability and support cross-functional decisions.
  • Proficient with iOS, iPadOS, macOS, Windows 10/11, and virtualization technologies.
  • Experienced in collaborating with DevOps and Agile teams
  • Strong background in system orchestration and integration.
  • Proven UEM expertise (Intune, Microsoft Endpoint Manager, Jamf) in provisioning, deployment, updates, and policy management.
  • Skilled in automation using PowerShell and Bash scripting.
  • Experienced in packaging software for large-scale deployment on Windows and Mac.
  • Track record of delivering business-aligned solutions that drive digital transformation across functions.
Responsibilities
  • Serve as the domain expert driving business value from Amgen’s device technologies by defining, architecting, operating, and maintaining end-user computing platforms— including PCs, mobile devices, tablets, and virtual desktops (W365 VDI)—while establishing and managing short- and long-term strategies and roadmaps for all device modalities.
  • Define architectural solutions by analyzing business needs, reviewing current environments, and integrating industry-leading standards in collaboration with operations, enablement, and enterprise architecture teams.
  • Establish standards, deployment methods, and supported configurations for IS-provisioned Windows, Mac, and iOS devices, in alignment with Amgen IS device lifecycle policies and procedures.
  • Design and define next-generation desktop management platforms and processes, focusing on Modern Device and Unified Endpoint Management.
  • Define hardware standards to meet current needs and guide future device selection with a strong understanding of enterprise IT. Provide data-driven feedback and testing on new devices (Windows, Mac, iOS) to ensure compliance and audit alignment.
  • Develop and maintain systems, tools, policies, and processes to deploy and support applications and workforce services on end-user devices enterprise wide.
  • Partner with IT teams including Cyber Security, Network Administration, and Deskside Services to gather requirements and support the procurement of end-user computing devices.
  • Define, track, publish, and manage key metrics to demonstrate improvements in stability, usage, and efficiency.
  • Oversee testing and qualification of all desktop and laptop software and updates, ensuring compliance with audit and regulatory requirements.
  • Build strong vendor relationships, leverage beta programs and user feedback forums, provide technical oversight, and guide vendor roadmap alignment.
  • Actively engage in critical outages, issue resolution, and capacity/availability planning sessions.
  • Lead strategic IS projects and initiatives.
Desired Qualifications
  • **S**caled Agile Framework (SAFe) for Teams (preferred)

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • MariTide's four-to-six-dose regimen could improve adherence and support obesity launch uptake.
  • IMDYLLTRA's Phase 3 survival benefit strengthens Amgen's oncology pipeline and commercial credibility.
  • Repatha growth, strong free cash flow, and AI efficiency support margin expansion.[1]

What critics are saying

  • Prolia's declining sales expose Amgen to erosion in its mature osteoporosis franchise.
  • MariTide still faces Phase 3, manufacturing, and tolerability execution risk before launch.
  • Tavneos regulatory scrutiny and tarlatamab safety concerns can limit near-term revenue conversion.

What makes Amgen unique

  • Amgen spans oncology, inflammation, rare disease, and general medicine across 100 countries.[1][3]
  • It combines biologics manufacturing with AI-driven discovery and development workflows.[1][5]
  • MariTide and IMDYLLTRA give Amgen distinct obesity and small-cell lung cancer growth options.[1]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Amgen who can refer or advise you

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE